Author of

• 20156

  +

  P1.07 - Immunology and Immunotherapy (ID 693)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Immunology and Immunotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22696

    +

    P1.07-028 - Determination of Soluble PD-L1 as a Potential Biomaker for Anti-PD(L)1 Therapy in Non-Small Cell Lung Cancer (NSCLC) (ID 9781)

    09:30 - 09:30  |  Author(s): C. Zamora Atenza
    • Abstract

    Background:
    PD-L1 has been established as a predictive marker for anti-PD(L)1 treatment, although patients negative for PD-L1 may also respond to those treatments. Soluble PD-L1 (sPD-L1) in blood has been described as prognostic factor in advanced NSCLC. To date, no evidence of efficacy of anti-PD(L)1 treatment according to sPD-L1 has been reported. The objective of this study is the correlate the efficacy of anti-PD(L)1 treatment according to sPD-L1 in our patients.
    
    Method:
    Baseline sPL-L1 levels were prospectively determined in pretreated advanced NSCLC patients receiving anti-PD(L)1 treatment. sPD-L1 levels (high (H) and low (L)), were calculated based on the median value of sPD-L1, and those values were correlated with OS and PFS for all patients and for according to histology. sPD-L1 levels were also correlated with leucocyte and platelet count and PD-L1 expression in tumor.
    
    Result:
    

    	sPD-L1
    	OS (m)		PFS (m)
    	H	L	H	L
    Adenocarcinoma (n: 19)	10.3 (5.3-17.4)	14.3 (10.1-18.5)	5.8 (0.9-10.7)	8.7 (4.0-13.4)
    	P 0.7		P: 0.7
    Squamous cell carcinoma (n: 11)	16.1 (7.5-24.8)	14.7 (9.4-20.0)	11.4 (2.5-20.3)	6.9 (3.2-10.7)
    	P: 0.8		P:0.7
    All (n:30)	13.2 (9.2-17.2)	15.4 (12.0-18.9)	4.2 (0.4-7.9)	6.0 (0.6-11.3)
    	P: 0.2		P: 0.5

    In patients with adenocarcinoma, a positive correlation was observed between sPD-L1 levels and monocyte count (R[2]:0.44; p: 0.0008), and with the ratio platelet/lymphocyte (R[2]:0.55; p<0.0001). In all NSCLC patients and squamous cell carcinoma, a positive correlation was observed between sPD-L1 levels and neutrophil count (R[2]:0.42; p: 0.002 and R[2]:0.59; p: 0.0025 respectively). No correlation between sPD-L1 level and PD-L1 expression in tumor was observed (n: 22 patients; p: 0.9065)
    
    Conclusion:
    Although no significant differences in OS or PFS were observed according to sPD-L1, a trend to a better OS was seen in NSCLC patients with low sPD-L1, especially in patients with adenocarcinoma. Prospective studies analyzing sPD-L1 levels and other PD-L1 variants are needed to find possible new biomarkers for anti-PD(L)1 treatments in NSCLC.